Brind.
  1. FDA is the source of guidance for U.S. healthcare providers.
  2. FDA is the source of guidance for U.S. healthcare providers.
  3. Eli Lilly and Company operates consistent with guidance provided by the FDA.
  4. Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.

Foghorn's FHD-909 trial advances with Eli Lilly and Company.

1 report, 1 independent Updated Aug 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Foghorn's FHD-909 trial advances with Eli Lilly and Company.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped